Biostem Technologies (BSEM) investor relations material

Executive summary

• Achieved 29% sequential revenue growth in Q2 2026, reaching $7.9 million, driven by Neox and Clarix product sales and hospital segment expansion.

• Uplisted to Nasdaq Capital Market after quarter end, enhancing visibility and access to capital.

• Completed the acquisition of BioTissue's surgical and wound care business in January 2026, expanding hospital revenue and product portfolio.

• Expanded commercial infrastructure, integrated CRM/ERP systems, and transitioned major GPO agreements to broaden hospital access.

• Substantial doubt exists about the ability to continue as a going concern due to liquidity needs and a $10M payment obligation related to the BioTissue acquisition.

Financial highlights

• Q2 2026 revenue was $7.9 million, up from $6.1 million in Q1 2026 but down from $11.0 million in Q2 2025, driven by hospital segment growth.

• Gross profit was $4.8 million with a 61% gross margin, flat sequentially but down from 94% in Q2 2025.

• Operating expenses were $13.2 million, up from $12.6 million in Q1 and 30% year-over-year, mainly due to commercial investments and higher amortization.

• GAAP net loss was $9 million ($0.52/share) vs. net income of $10,613 in Q2 2025; adjusted EBITDA loss was $4.6 million.

• Cash and equivalents were $7 million as of June 30, 2026, down from $13.7 million at March 31, 2026, and $29.5 million at year-end 2025.

Outlook and guidance

• Raised full-year 2026 revenue guidance to $26–$29 million, up from $25–$29 million.

• Expects sequential hospital revenue growth through year-end, with physician office segment stabilizing gradually.

• Operating expenses anticipated to remain flat sequentially, excluding Nasdaq uplisting costs.

• The company expects continued net losses and negative cash flows for at least the next twelve months due to CMS pricing changes and acquisition-related obligations.

• Additional debt or equity financing is required to meet obligations, including the $10M BioTissue payment due by September 15, 2026.